Cargando…
A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674455/ https://www.ncbi.nlm.nih.gov/pubmed/23686003 http://dx.doi.org/10.1038/bcj.2013.13 |
| _version_ | 1782272373841461248 |
|---|---|
| author | Hattori, Y Du, W Yamada, T Ichikawa, D Matsunami, S Matsushita, M |
| author_facet | Hattori, Y Du, W Yamada, T Ichikawa, D Matsunami, S Matsushita, M |
| author_sort | Hattori, Y |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3674455 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-36744552013-06-06 A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor Hattori, Y Du, W Yamada, T Ichikawa, D Matsunami, S Matsushita, M Blood Cancer J Letter to the Editor Nature Publishing Group 2013-05 2013-05-17 /pmc/articles/PMC3674455/ /pubmed/23686003 http://dx.doi.org/10.1038/bcj.2013.13 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
| spellingShingle | Letter to the Editor Hattori, Y Du, W Yamada, T Ichikawa, D Matsunami, S Matsushita, M A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor |
| title | A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor |
| title_full | A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor |
| title_fullStr | A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor |
| title_full_unstemmed | A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor |
| title_short | A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor |
| title_sort | myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674455/ https://www.ncbi.nlm.nih.gov/pubmed/23686003 http://dx.doi.org/10.1038/bcj.2013.13 |
| work_keys_str_mv | AT hattoriy amyelomacelllineestablishedfromapatientrefractorytothalidomidetherapyrevealedhighriskcytogeneticabnormalitiesandproducedvascularendothelialgrowthfactor AT duw amyelomacelllineestablishedfromapatientrefractorytothalidomidetherapyrevealedhighriskcytogeneticabnormalitiesandproducedvascularendothelialgrowthfactor AT yamadat amyelomacelllineestablishedfromapatientrefractorytothalidomidetherapyrevealedhighriskcytogeneticabnormalitiesandproducedvascularendothelialgrowthfactor AT ichikawad amyelomacelllineestablishedfromapatientrefractorytothalidomidetherapyrevealedhighriskcytogeneticabnormalitiesandproducedvascularendothelialgrowthfactor AT matsunamis amyelomacelllineestablishedfromapatientrefractorytothalidomidetherapyrevealedhighriskcytogeneticabnormalitiesandproducedvascularendothelialgrowthfactor AT matsushitam amyelomacelllineestablishedfromapatientrefractorytothalidomidetherapyrevealedhighriskcytogeneticabnormalitiesandproducedvascularendothelialgrowthfactor AT hattoriy myelomacelllineestablishedfromapatientrefractorytothalidomidetherapyrevealedhighriskcytogeneticabnormalitiesandproducedvascularendothelialgrowthfactor AT duw myelomacelllineestablishedfromapatientrefractorytothalidomidetherapyrevealedhighriskcytogeneticabnormalitiesandproducedvascularendothelialgrowthfactor AT yamadat myelomacelllineestablishedfromapatientrefractorytothalidomidetherapyrevealedhighriskcytogeneticabnormalitiesandproducedvascularendothelialgrowthfactor AT ichikawad myelomacelllineestablishedfromapatientrefractorytothalidomidetherapyrevealedhighriskcytogeneticabnormalitiesandproducedvascularendothelialgrowthfactor AT matsunamis myelomacelllineestablishedfromapatientrefractorytothalidomidetherapyrevealedhighriskcytogeneticabnormalitiesandproducedvascularendothelialgrowthfactor AT matsushitam myelomacelllineestablishedfromapatientrefractorytothalidomidetherapyrevealedhighriskcytogeneticabnormalitiesandproducedvascularendothelialgrowthfactor |